XTX Topco Ltd Purchases 3,787 Shares of Amgen Inc. (NASDAQ:AMGN)

XTX Topco Ltd lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 179.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,902 shares of the medical research company’s stock after purchasing an additional 3,787 shares during the period. XTX Topco Ltd’s holdings in Amgen were worth $1,902,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Zacks Investment Management bought a new stake in shares of Amgen in the third quarter valued at about $31,776,000. Zega Financial LLC acquired a new position in Amgen in the 3rd quarter valued at approximately $1,032,000. Zimmer Partners LP bought a new stake in shares of Amgen in the 3rd quarter worth approximately $5,800,000. Zurich Insurance Group Ltd FI grew its holdings in shares of Amgen by 3.5% during the 3rd quarter. Zurich Insurance Group Ltd FI now owns 130,288 shares of the medical research company’s stock worth $41,980,000 after purchasing an additional 4,402 shares in the last quarter. Finally, iA Global Asset Management Inc. increased its position in shares of Amgen by 3.9% during the third quarter. iA Global Asset Management Inc. now owns 54,774 shares of the medical research company’s stock valued at $17,649,000 after purchasing an additional 2,077 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. UBS Group lowered their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. TD Cowen raised their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $323.05.

Amgen Price Performance

Shares of AMGN stock opened at $272.58 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $146.52 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 3.08 and a beta of 0.55. The firm’s 50 day moving average is $306.58 and its 200-day moving average is $315.82. Amgen Inc. has a 1 year low of $257.80 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $4.96 EPS. Sell-side analysts forecast that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.30%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.